Research and preclinical development
The heart of our antibody discovery platform is Symplex®, which is our proprietary PCR method for cloning all antigen specific antibodies from single sorted B cells purified from animals. Optimized procedures then allow us to express the entire repertoire of full-length antibodies and perform multiparameter screening, which include binding, epitope bin, affinity, function, immunogenicity and quality. Coupled with next generation sequencing this provides us with a six-dimensional property space for each of thousands of antigen specific antibodies from which we can select leads with optimal set of properties.
The productivity of our antibody discovery process is evidenced by the size and diversity of the repertoires of high-quality antibodies from multiple species that we have generated for our partners and internal.
The technology platform may also be used for indications outside of cancer.
Competitive timelines to IND
Symphogen has proven its ability to deliver unique antibodies on aggressive timelines as exemplified with our filing of three INDs in six months – Sym021, Sym022 and Sym023. Such an exceptional achievement is made possible by the unique way we run projects. Developability assessment is an integrated part of the lead selection process, which means that potential critical features of the lead candidates are taken into consideration very early in the development path.
Once the lead is selected, pre-clinical development is based on a solid, standardized platform where only minor adaption to the lead is typically needed, a balanced out-sourcing strategy and a cross-functionally aligned development plan, where critical path activities are staggered to minimize the overall timeline.
Publications
Sym015: A highly efficacious antibody mixture against MET amplified tumors
PMID: 28679766 [PubMed - as supplied by publisher]
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Phase I dose-escalation trial of Sym004, a mixture of two anti-EGFR antibodies, in Japanese patients with advanced solid tumors
Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck.
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab
Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor
Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor
Sym004: A Novel Synergistic Anti–Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy